Headache

Chronic Migraine

Chronic Migraine ยท G43.7

Chronic migraine is a condition in which headaches occur 15 or more days per month for over three months, with at least 8 of those days exhibiting migraine features. Approximately 2.5-3% of episodic migraine patients progress to chronification annually, resulting in reduced quality of life and significant socioeconomic burden.

2026-03-26

At a Glance

Chronic migraine is a disorder in which headaches persist for more than 15 days per month for over three months. It affects approximately 1.4-2.2% of all adults. Analgesic overuse, stress, obesity, and sleep disorders are major causes of chronification. Reducing analgesic use and employing preventive medications (topiramate, Botox, etc.) can decrease headache frequency. Regular lifestyle habits and keeping a headache diary are helpful for management.

Definition and Overview

Chronic migraine is a condition in which headaches occur 15 or more days per month for more than three months, with at least 8 of those days exhibiting migraine features [1]. The process by which headache frequency gradually increases in patients who previously had episodic migraine, converting to chronic migraine, is termed "migraine chronification."

Approximately 1.4-2.2% of the adult population worldwide meets the criteria for chronic migraine [2]. Approximately 2.5-3% of episodic migraine patients convert to chronic migraine annually [2]. Chronic migraine causes greater impairment of daily life than episodic migraine, involves more frequent hospital visits, and is commonly accompanied by comorbidities such as depression and anxiety.

Etiology

The causes of migraine chronification are divided into modifiable factors related to lifestyle and non-modifiable factors [2].

Modifiable factors include analgesic overuse (10-15 or more days per month), obesity (BMI 30 or higher, 1.4-fold increased risk), excessive caffeine intake (more than 400mg per day), sleep disorders (insomnia, sleep apnea), stress, and comorbid depression or anxiety [3].

Non-modifiable factors that have been reported include female sex, lower socioeconomic status, history of head trauma, and high baseline headache frequency (10 or more days per month) [2].

Frequent use of analgesics weakens the brain's pain-suppressing function. This leads to heightened pain sensitivity and increased headache frequency [3]. Population-based studies have identified analgesics containing sedative components (2.06-fold risk) and opioid analgesics (1.98-fold risk) as independent risk factors for chronification [3].

Repeated migraine attacks gradually sensitize the brain's pain-processing neurons. These sensitized neurons begin responding to stimuli that would not normally produce pain. Allodynia -- experiencing pain from light touch -- occurs in approximately 60-70% of chronic migraine patients, compared to approximately 30-40% of episodic migraine patients, demonstrating this phenomenon [2].

Neuroimaging studies in chronic migraine patients have reported volume reduction in brain regions involved in pain modulation and increased white matter lesions [2]. Whether these changes are causes or consequences remains to be determined, but they suggest structural alterations in the brain's pain modulation system.

Symptoms

The main symptoms of chronic migraine are as follows.

  • Headaches persisting 15 or more days per month
  • At least 8 of those days exhibit migraine characteristics: unilateral pulsating pain, moderate to severe intensity, aggravation by routine physical activity
  • Hypersensitivity to light or sound
  • Accompanying nausea or vomiting
  • Allodynia -- pain from light touch (present in approximately 60-70%)
  • Fatigue, reduced concentration, mood changes

Approximately 30-50% of chronic migraine patients have comorbid depression, and 30-50% have comorbid anxiety disorders [2].

Diagnosis

The international diagnostic criteria for chronic migraine are as follows [1].

A. Headaches occur 15 or more days per month for more than three months.
B. There have been at least five episodes meeting migraine diagnostic criteria.
C. For more than three months, on at least 8 days per month, headaches meet one of the following: (1) migraine diagnostic criteria, (2) migraine with aura criteria, (3) headaches believed to be migraine and effectively treated with triptans or similar medications.
D. Not better accounted for by another diagnosis.

When analgesic overuse is present, both chronic migraine and medication-overuse headache are diagnosed simultaneously. After discontinuation of analgesic overuse, if headaches decrease to fewer than 15 days per month over a two-month observation period, the diagnosis is reclassified as episodic migraine.

Analgesic overuse is present in approximately 50-80% of chronic migraine patients [1]. Medication-overuse headache is diagnosed when simple analgesics are used 15 or more days per month, or triptans or combination analgesics are used 10 or more days per month for more than three months [1].

Treatment

Analgesic Overuse Discontinuation

The first step in treating chronic migraine with analgesic overuse is discontinuation of the overused medication. Withdrawal symptoms such as rebound headache, nausea, anxiety, and sleep disturbance may occur for 2-10 days after discontinuation, but most resolve within 2-8 weeks. Research indicates that analgesic overuse discontinuation alone achieved a meaningful reduction in headache frequency in approximately 50% of patients [3].

Preventive Pharmacotherapy

Among preventive medications for chronic migraine, topiramate and Botox injection (botulinum toxin type A) have the highest level of evidence [4][5].

Topiramate demonstrated an additional reduction of 3.5 monthly migraine days compared to placebo in clinical trials [5]. Botox injection reduced monthly headache days by an additional 1.4-2.3 days compared to placebo at 12 weeks in large-scale clinical trials, and 24-week treatment resulted in an average reduction of 8-9 monthly headache days from baseline [4].

CGRP (calcitonin gene-related peptide) targeted therapies are a new class of preventive medications that block substances involved in migraine pathogenesis. They are used as additional treatment options for patients with inadequate response to conventional preventive medications.

Neuromodulation Therapy

Prognosis and Complications

Without appropriate treatment, chronic migraine tends to maintain or worsen in headache frequency and intensity. The likelihood of comorbid depression, anxiety disorders, and sleep disturbance increases, and economic losses due to work absenteeism and reduced productivity are approximately 4-5 times greater than for episodic migraine [2].

With appropriate preventive treatment combined with lifestyle modification, headache frequency can be reduced to episodic migraine levels in a substantial number of patients. Improvement has been reported in approximately 50% of patients with analgesic overuse discontinuation alone [3].

Lifestyle Guide

Lifestyle recommendations for chronic migraine management are as follows.

  • Limit analgesic use to no more than 2-3 times per week and record the number of days of use in a headache diary.
  • Maintain regular sleep habits. Going to bed and waking up at the same time every day is recommended.
  • Engage in aerobic exercise for at least 30 minutes, at least three times per week.
  • Limit caffeine intake to 200mg or less per day (approximately 2 cups of coffee).
  • Practice relaxation techniques or breathing exercises for stress management.
  • Keep a headache diary to identify triggers (food, environment, stress, etc.).
  • If depression or anxiety persists, seek concurrent psychiatric care.
  • If overweight, aim to maintain an appropriate body weight.

Frequently Asked Questions

Chronic migraine is diagnosed when headaches occur 15 or more days per month, with at least 8 days exhibiting migraine features, persisting for more than three months. In most cases, patients who previously had episodic migraine experience a gradual increase in headache frequency leading to chronification.

Taking analgesics too frequently is one of the most common causes. Using simple analgesics 15 or more days per month, or triptans 10 or more days per month, can paradoxically lead to medication-overuse headache. Additionally, stress, obesity, sleep disorders, excessive caffeine intake, and comorbid depression or anxiety can accelerate chronification.

Analgesic overuse accompanies approximately 50-80% of chronic migraine patients. Frequent analgesic use paradoxically sensitizes the brain's pain detection capacity, creating a vicious cycle of increasingly frequent headaches. Discontinuing the overused medication may be difficult for the first 2-8 weeks, but improvement often follows. We recommend working with a specialist to develop a plan.

Yes, with appropriate treatment, many patients can return to an episodic migraine state. Treatment includes preventive medications (topiramate, Botox, etc.), CGRP targeted therapy, analgesic overuse discontinuation, and lifestyle modification. Research has confirmed that Botox treatment reduces monthly headache days by an average of 8-9 days.

Chronic migraine has a significantly greater impact on quality of life compared to episodic migraine. Depression and anxiety disorders accompany approximately 30-50% of patients, and the economic burden from work absenteeism and reduced productivity is substantial. Rather than enduring it alone, active management through specialist consultation can lead to meaningful improvement.

The most important thing is to avoid overusing analgesics. Maintain regular sleep, meal, and exercise habits, and keeping a headache diary is very helpful for identifying triggers. Reducing caffeine intake is also recommended. If depression or anxiety is present, we recommend considering concurrent psychiatric treatment.

References

  1. [1] Headache Classification Committee of the International Headache Society (2018). "The International Classification of Headache Disorders, 3rd edition." Cephalalgia, 38: 1-211. DOI PubMed
  2. [2] May A, Schulte LH (2016). "Chronic migraine: risk factors, mechanisms and treatment." Nature Reviews Neurology, 12: 455-464. DOI PubMed
  3. [3] Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB (2008). "Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study." Headache, 48: 1157-1168. DOI PubMed
  4. [4] Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010). "OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program." Headache, 50: 921-936. DOI PubMed
  5. [5] Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J (2007). "Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial." Headache, 47: 170-180. DOI PubMed
Chronic MigraineMigraine ChronificationMedication-overuse HeadacheMigraine Preventive TherapyBotox MigraineMigraine Diagnosis

This content is provided for medical information purposes only and cannot replace professional medical advice. If you have symptoms, please consult a specialist.

Are you concerned about related symptoms?

Get an accurate diagnosis at OSANG Neurosurgery.